Pear Therapeutics

Pear claims breakthrough tag for alcohol use disorder DTx

Digital health company Pear Therapeutics has won FDA breakthrough device status for reSET-A, its development-stage prescription digital therapeutic (DTx) for people with alcohol-use disorder. The DTx – also known as Pear-009 – is still in the proof-of-concept trial stage, but draws on the same cognitive behavioural therapy (CBT) deployed in Pear’s commercial-stage products reSET and …

Pear claims breakthrough tag for alcohol use disorder DTx Read More »

Digital therapeutic cuts opioid use disorder care costs, says study

A real-world study of digital therapeutic (DTx) for opioid use disorder has found that patient show used it had 46% fewer hospital stays than a control group, saving more than $2,700 over a nine-month period. The study of Pear Therapeutics’ reSET-O found that the total cost of hospital and clinician costs were $11,141 among 64 …

Digital therapeutic cuts opioid use disorder care costs, says study Read More »

Top 20 Innovative Digital Therapeutics Companies of 2020

The digital therapeutics market has unsurprisingly exploded in the past year. Available virtually, digital therapies are developed by clinicians & scientists and are rigorously tested, making it possible for people to access treatment for both physical & psychological conditions at home Demand for digital therapies has skyrocketed amid the COVID-19 pandemic. As a result, many …

Top 20 Innovative Digital Therapeutics Companies of 2020 Read More »

#Healthin2Point00, Episode 218 | Bicycle, NexHealth, Stork Club, DrChrono & Pear Therapeutics

On Episode 218 of Health in 2 Point 00, it’s a big week in digital health for IPOs. Today Jess asks me about Bicycle Health’s $27 million Series A, bringing the substance use disorder startup’s total to $32.3 million. NexHealth, which is like Shopify for doctors, gets $31 million in a Series B, Stork Club …

#Healthin2Point00, Episode 218 | Bicycle, NexHealth, Stork Club, DrChrono & Pear Therapeutics Read More »

Ohio is third state to fund Pear’s digital therapeutics to tackle addiction

A third US state has agreed to fund Pear Therapeutics’ digital therapeutics (DTx) to treat people with substance and opioid use disorders.  The company has been pushing for more reimbursement of its three marketed DTx products in the US following a first FDA approval in 2017. Pear said that the Ohio Department of Mental Health …

Ohio is third state to fund Pear’s digital therapeutics to tackle addiction Read More »

Treating Patients with Software: Digital Therapeutics

The 3rd generation pharmaceuticals- Digital therapeutics- have become a much-discussed aspect of MedTech today, as they compete with established drug-based pharmaceutical and biotech products to become therapeutic interventions for many acute and chronic diseases. Currently, many small- and mid-size companies are working to develop, manufacture and launch their software-based therapeutic interventions, while we are observing …

Treating Patients with Software: Digital Therapeutics Read More »

Pear Therapeutics Raises $80M to Advance Prescription Digital Therapeutics

What You Should Know: – Pear Therapeutics today announced that it has successfully closed an $80 million Series D financing led by SoftBank Vision Fund 2. –  Pear is the leader in prescription digital therapeutics and the first company to receive FDA authorization for a prescription digital therapeutic (PDT) to treat disease. – Pear currently …

Pear Therapeutics Raises $80M to Advance Prescription Digital Therapeutics Read More »

PharmaShots Weekly Snapshot (Nov 16-20, 2020)

Eli Lilly and Incyte Receive FDA’s EUA for Baricitinib + Remdesivir to Treat Hospitalized Patients with COVID-19 Published: Nov 20,2020 | Tags: baricitinib, COVID-19, Eli Lilly, Emergency Use Authorization, FDA’s, Incyte, receives, Remdesivir Novartis Signs a License Agreement with Mesoblast to Develop and Commercialize Remestemcel-L for ARDS Published: Nov 20,2020 | Tags: Agreement, ARDS, Commercialize, …

PharmaShots Weekly Snapshot (Nov 16-20, 2020) Read More »

Pear Therapeutics Launches Somryst Insomnia App Via an End-to-End Virtual Care Experience

Shots: Pear Therapeutics launches Somryst as the first PDT intended for use in the treatment of patients with chronic insomnia aged > 22yrs. It addresses the issues of chronic insomnia by delivering (CBTi) approach that trains the brain and body to sleep In a study of ~1,400 adults with CI, PDT reduced the amount of …

Pear Therapeutics Launches Somryst Insomnia App Via an End-to-End Virtual Care Experience Read More »

Digital therapies for opioid use disorder need more data, says ICER

There isn’t enough evidence to suggest that digital therapies for people with opioid use disorder (OUD) can improve on standard interventions, according to the Institute for Clinical and Economic Review. The US cost-effectiveness watchdog has concluded in an evidence report that none of three digital therapies under scrutiny – apps from Pear Therapeutics, Chess Health …

Digital therapies for opioid use disorder need more data, says ICER Read More »

Top 20 Innovative Digital Therapeutics Companies of 2019

The recent decades have shown an accelerated development and evolution in the technology world, leading to unexpected growth in digital health companies. The Digital Therapeutics companies aid patients to schedule appointments, view medical records and seek medical advice without visiting clinics or hospitals. With the aid of health information technology, wearable devices, telehealth, telemedicine, and …

Top 20 Innovative Digital Therapeutics Companies of 2019 Read More »